Acelity launches PREVENA DUO Incision Management System Platform

Acelity is the market leader in leveraging innovation to advance the art of healing. Acelity is applying that expertise to help clinicians better manage surgical incisions with the aim of reducing complications, expediting recovery and reducing unnecessary expense.

In fact, more than 70 clinical publications supporting negative pressure incision management have been published. The effectiveness of the PREVENA Incision Management System or incisional V.A.C. Therapy have established Acelity as the principal authority on the use of negative pressure for closed incisions.

“We are finding that surgeons around the world are adopting PREVENA Therapy as standard practice to provide care for their post-operative patients,” said Ron Silverman, M.D., Chief Medical Officer, Acelity.

“With the introduction of the PREVENA DUO Platform, Acelity is able to provide the same proven clinical benefits of negative pressure therapy that is specially configured for procedures where there are two closed incisions on the patient.”

There are eight million people at risk for healthcare-associated infections (HAIs), and post-surgical complications can lead to significant costs. According to research published in The New England Journal of Medicine, surgical site infections (SSIs) are 21.8% of all HAIs, and these infections increase average length of hospital stay by an extra 9.58 days at an additional cost of $38,656.

“SSIs encompass more than 20% of all HAIs and represent a significant burden both financially and psychologically for the patient, so there is a need to proactively address this issue,” said Allen Gabriel, MD of PeaceHealth Medical Group Plastic Surgery.

“With the PREVENA Incision Management System, surgeons can rely upon a significant body of clinical evidence demonstrating the system’s efficacy and coupled with its ease of use, ensures that we are doing all we can to help reduce this burden in an effort to improve outcomes for patients.”

Clinical studies have demonstrated the efficacy of PREVENA Incision Management System in significantly reducing the incidence rate of infections. According to one study led by Tim Matatov, M.D., Louisiana State University Health Sciences Center, evaluating the PREVENA Incision Management System in reducing the risk of groin wound infection after vascular surgery, PREVENA Therapy was found to reduce the incidence of groin wound infection compared to traditional skin adhesive or absorbent dressings (6% incidence of infection with PREVENA Therapy compared to 30% with control group). 

As groin incisions are prone to complications and the incidence of groin SSIs after vascular surgery can be as high as 44 %, prevention is a key component of improving patient care.

The results also indicated significant cost savings with the PREVENA Incision Management System. In fact, the study authors concluded that the cost of the PREVENA System was quickly exceeded by the traditional dressings group due to long hospitalisation required for two patients with Szilagyi Grade III infections ($25,740 vs. > $45,000 respectively).

“Until now, clinicians did not have the option to manage two incisions simultaneously with a single, disposable negative pressure source. The new PREVENA DUO Platform offers one efficient, easy-to-use method for providing therapy to these patients,” added Dr. Silverman.